Fatty liver disease does commonly drive abnormal cholesterol levels, though the lipid picture it creates is more specific than a simple jump in total cholesterol. The hallmark pattern involves elevated triglycerides, a shift toward smaller and denser LDL particles, lower HDL, and a rise in a protein called apolipoprotein B that ferries cholesterol through the bloodstream. In a large population study, roughly six out of ten people with fatty liver had at least one of these apolipoprotein B-related lipid abnormalities, compared with fewer than two in ten without the condition. Understanding how a struggling liver reshapes your cholesterol numbers matters because cardiovascular disease, not liver failure, is the leading killer among people with fatty liver.
How a Fatty Liver Reshapes Your Lipid Profile
When people hear “high cholesterol,” they usually picture a single number on a lab printout. Fatty liver rarely causes a dramatic spike in total cholesterol the way, say, a genetic condition like familial hypercholesterolemia does. Instead, it warps the overall lipid profile in ways that are easy to miss if you only glance at the headline number. Triglycerides climb, HDL (the so-called good cholesterol) drops, and LDL particles become smaller and denser. Standard lab panels measure LDL cholesterol by concentration, and that number can look only mildly elevated or even normal. But the particles carrying that cholesterol are more numerous and more likely to lodge in artery walls.
A large cross-sectional analysis from the Lifelines cohort found that any apolipoprotein B-related lipid disorder was present in about 61.5% of people with fatty liver, versus 16.5% of those without it. Each type of apoB-linked abnormality was independently associated with fatty liver after adjusting for age and sex. The one exception was that classic LDL cholesterol elevation alone was not especially more common in fatty liver, reinforcing the idea that the standard LDL number does not capture the full story.1Elsevier / PubMed Central. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study
Research on LDL subclasses adds detail here. People with the inflammatory form of fatty liver (called NASH or MASH) tend to have lower levels of the larger, less harmful LDL1 particles and higher proportions of smaller, denser LDL3 and LDL4 particles. In one study, NASH was independently associated with elevated small dense LDL even after accounting for other metabolic factors.2ScienceDirect / Journal of Clinical Lipidology. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease This shift toward small dense particles is significant because they are considered more atherogenic, meaning they are better at starting the plaque buildup that leads to heart attacks and strokes.
What Happens Inside the Liver
A healthy liver acts as a clearinghouse for fats and cholesterol. It pulls fatty acids from the blood, uses some for energy, packages the rest into particles called VLDL, and ships them out. When excess fat accumulates in liver cells, the system goes into overdrive. Insulin resistance, which is present in the vast majority of fatty liver cases, plays a central role: it fails to suppress the normal breakdown of fat tissue, so a flood of fatty acids pours into the liver. At the same time, the liver ramps up its own fat-making machinery through a process called de novo lipogenesis.
Insulin normally helps regulate specialized receptors in the liver that coordinate both cholesterol and fatty acid production. Research in hepatic tissue has shown that these receptors, known as Liver X Receptors, are important insulin-mediating factors in lipid production, sitting at a crossroads between cholesterol balance and fat synthesis.3Journal of Biological Chemistry. Liver X Receptors as Insulin-mediating Factors in Fatty Acid and Cholesterol Biosynthesis When insulin signaling goes haywire, the liver churns out more VLDL particles, each loaded with triglycerides and apolipoprotein B. That flood of VLDL eventually gets remodeled in the bloodstream into the small, dense LDL particles that do the most arterial damage.
As the disease progresses from simple fat accumulation to the inflammatory stage, toxic lipid intermediates pile up. Saturated fatty acids, free cholesterol, and ceramides accumulate and send signals to immune and scarring cells in the liver, reinforcing a cycle of inflammation and fibrosis.4PubMed Central. MASH: the nexus of metabolism, inflammation, and fibrosis Free cholesterol itself becomes part of the problem at this stage, contributing to cell damage within the liver while also spilling into the circulation.
Which Direction Does the Causation Run?
A reasonable question is whether the relationship works the other way around: does high cholesterol cause fatty liver? Observational studies have found that people with abnormal lipids are more likely to develop fatty liver, but correlation alone cannot sort out the cause and effect. A Mendelian randomization study addressed this head-on by using genetic variants as stand-ins for lifelong exposure to various lipid levels. This approach acts as a natural experiment because the genetic variants are assigned at birth, before any lifestyle factors kick in. The findings did not support dyslipidemia as a causal factor for fatty liver.5PubMed Central. Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease
This does not mean lipids are irrelevant to the liver’s health, but it strongly suggests that the dominant direction of causation is from fatty liver to disordered lipids, not the reverse. The practical implication is straightforward: treating the liver disease itself may be a more effective strategy for fixing the lipid profile than trying to lower cholesterol numbers in isolation.
Why Heart Disease Is the Real Danger
Most people diagnosed with fatty liver worry about cirrhosis. That concern is valid, but it is not the most likely way fatty liver will harm you. Cardiovascular disease remains the leading cause of death among people with the condition.6PubMed Central. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review The atherogenic lipid profile described above is a major reason why. People with fatty liver face elevated risks for coronary heart disease, heart rhythm problems, and heart muscle dysfunction, all of which translate into higher rates of heart attacks and cardiovascular deaths.7PubMed Central. NAFLD and cardiovascular diseases: a clinical review
The connection is not just about cholesterol numbers, either. Fatty liver is an inflammatory condition, and that chronic low-grade inflammation spills beyond the liver to affect blood vessels throughout the body. The combination of atherogenic lipids, insulin resistance, elevated blood pressure, and systemic inflammation creates a cardiovascular risk profile that adds up to more than the sum of its parts.
The Pattern Shows Up Even in Lean People
Fatty liver is often assumed to be a disease of obesity, but a meaningful percentage of people who develop it are not overweight. This so-called lean fatty liver is more common than many clinicians appreciate, and it carries its own metabolic baggage. A meta-analysis comparing lean individuals with and without fatty liver found that even without excess body weight, lean people with the condition had significantly higher triglycerides (about 48 mg/dL higher), modestly elevated total cholesterol (about 7 mg/dL higher), and the full spectrum of metabolic syndrome risk factors including elevated blood pressure and insulin resistance.8PubMed. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients
A study in elderly Chinese adults found that lean people with fatty liver had higher triglyceride-to-HDL ratios, higher fasting glucose, and greater rates of hypertension and diabetes compared with lean healthy controls. The prevalence of fatty liver rose steeply with the triglyceride-to-HDL ratio: from about 14% in those with the lowest ratio to nearly 60% in those with the highest.9PubMed Central. Metabolic characteristics and risk profile of non-obese fatty liver disease in an elderly Chinese community cohort Even compared with obese people who do not have fatty liver, lean people with the condition show a similar degree of dyslipidemia.10PubMed Central. Non-alcoholic fatty liver disease in lean individuals
The takeaway: if you are lean, a fatty liver diagnosis should not be dismissed as a minor incidental finding. The lipid disturbances and cardiovascular risk can be just as real as in someone who is overweight.
Children Are Not Immune
With childhood obesity rates rising, pediatric fatty liver has become increasingly common, and the lipid abnormalities it causes in kids closely mirror the adult pattern. In one pediatric cohort, the prevalence of lipid disorders was striking: 88% had elevated triglycerides, 77% had low HDL, 58% had elevated non-HDL cholesterol, and 42% had high total cholesterol.11PubMed Central. Dyslipidemia is associated with pediatric nonalcoholic fatty liver disease Those numbers are far higher than in age-matched children without fatty liver.
What makes the pediatric data especially concerning is that the severity of liver injury correlates directly with how atherogenic the lipid profile becomes. Children with the inflammatory form of the disease had markedly worse lipid ratios than those with simple fat accumulation, and both disease severity and fibrosis stage remained independent predictors of an atherogenic profile even after adjusting for obesity and insulin resistance.12Pediatric Research. Severity of Liver Injury and Atherogenic Lipid Profile in Children With Nonalcoholic Fatty Liver Disease In other words, the worse the liver looks under a microscope, the more dangerous the cholesterol picture becomes, and this link starts early in life.
Are Statins Safe When You Have Fatty Liver?
This is one of the most common questions patients and even some doctors get wrong. For decades, there was a widespread reluctance to prescribe statins to people with liver disease because of fears of liver toxicity. The concern was understandable on its face: statins are processed by the liver, and routine blood tests sometimes show mild liver enzyme elevations in people taking them. But the evidence has shifted decisively. Statins do not need to be avoided in patients with fatty liver disease, fatty liver inflammation, or even compensated cirrhosis when there is a clear cardiovascular indication for their use.13PubMed Central. Statins and its hepatic effects: Newer data, implications, and changing recommendations
In fact, evidence suggests statins may do more than just lower cardiovascular risk in this population. Research indicates they are not only effective at reducing cardiovascular events in people with fatty liver, but they may also have beneficial effects on the liver itself.14PubMed. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes The old hesitancy to prescribe statins for fatty liver patients is, at this point, doing more harm than good. If your cardiovascular risk warrants statin therapy, having fatty liver is not a reason to skip it.
Exercise Improves Both Problems Simultaneously
One of the more encouraging findings in this area is that exercise can reduce both liver fat and LDL cholesterol even when it does not lead to significant weight loss. A meta-analysis of exercise interventions in people with fatty liver found that physical activity significantly lowered liver fat content, LDL cholesterol, and triglycerides compared with sedentary controls, independent of changes in body weight.15PubMed Central. Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis This is meaningful because many people feel discouraged when exercise does not immediately show up on the scale.
Resistance training deserves specific mention. A randomized trial comparing resistance training to stretching in people with fatty liver found that the resistance training group had significant reductions in liver fat, trunk fat, and total cholesterol, along with gains in lean body mass. The reduction in liver fat did not correlate with overall weight change but did correlate with loss of trunk fat specifically.16PubMed Central. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial Lifting weights, in other words, can help even when the scale does not budge much.
Diet, Fructose, and the Cholesterol Connection
What you eat shapes both the liver fat burden and the resulting lipid disturbances. Fructose has drawn particular scrutiny. In animal studies, fructose intake drives up both plasma and liver total cholesterol, raises LDL, drops HDL, and boosts the liver enzymes responsible for making cholesterol internally. Mice lacking the key enzyme for fructose processing had significantly less liver fat and lower cholesterol when fed fructose compared with normal mice.17PubMed Central. The sweet path to metabolic demise: fructose and lipid synthesis Saturated fat intake produces similar results. In controlled feeding experiments, both fructose and saturated fat elevated the liver’s cholesterol-manufacturing machinery and worsened the atherogenic lipid profile, including rising apoB levels and falling protective apoA1 levels.18PubMed. Hepatic cholesterol synthesis and lipoprotein levels impaired by dietary fructose and saturated fatty acids in mice: Insight on PCSK9 and CD36
This is one area where much of the evidence comes from animal models, so the exact magnitudes do not translate directly to humans. But the direction is consistent and aligns with clinical observations: diets high in added sugars and saturated fats worsen both liver fat and blood lipids through overlapping pathways. Reducing intake of sugary beverages and highly processed foods is one of the most accessible interventions for addressing both problems.
Emerging Drugs That Target Liver and Lipids Together
For years, no approved medication specifically treated fatty liver disease. That changed with resmetirom, a drug that activates thyroid hormone receptors selectively in the liver. In a phase 3 trial, resmetirom at the 100 mg dose reduced LDL cholesterol by about 14% relative to placebo, apolipoprotein B by about 16.5%, and triglycerides by about 23% in those with elevated baseline levels. It also cut liver fat by roughly 45% at 16 weeks, and that reduction was sustained over a year.19Nature Medicine. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial A meta-analysis of the resmetirom data confirmed that LDL reductions and triglyceride reductions were both significantly greater in the drug group than in placebo.20PubMed Central. Effectiveness of Resmetirom in Reducing Cholesterol Levels in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Another class of drugs under investigation, the dual PPAR agonists, also shows promise. Saroglitazar improved levels of small dense LDL cholesterol in patients with fatty liver, a particularly relevant target given the atherogenic particle shift discussed earlier.21PubMed. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis These dual-purpose therapies are appealing because they address the liver disease and its downstream cardiovascular risk at the same time, rather than treating each in isolation.
Genetics Can Push the Pattern in Unexpected Directions
Not everyone with fatty liver develops the same lipid profile, and genetics help explain some of the variation. One of the most interesting examples involves a variant in a gene called TM6SF2. People who carry the E167K variant of this gene are more prone to fatty liver, but they tend to have lower circulating lipid levels, not higher. The variant appears to impair the liver’s ability to export fat-laden particles into the bloodstream. In mouse models fed a high-fat diet, carrying this variant led to significantly more fat trapped inside the liver while altering the balance of fatty acid types stored there.22PubMed Central. TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
This creates a paradox: the liver is more damaged, but the blood lipids look deceptively benign. Clinicians relying on cholesterol numbers alone might underestimate the severity of liver disease in someone carrying this variant. It is a good illustration of why fatty liver management benefits from looking beyond the standard lipid panel.
Bile Acids, the Gut, and a Less Obvious Cholesterol Pathway
The liver converts cholesterol into bile acids, which it sends to the gut to help digest fat. Gut bacteria then modify those bile acids, and the modified versions get recirculated back to the liver. This loop is one of the body’s primary routes for cholesterol disposal. In people with fatty liver inflammation, the system malfunctions: bile acid transporters in the liver get turned down by inflammation, allowing conjugated bile acids to build up in the blood and liver.23PubMed Central. Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease
Changes in gut bacteria composition further compound the problem. When the microbial balance shifts, the ratio of different bile acid types changes, which in turn disrupts signaling through a receptor called FXR that normally helps regulate cholesterol and glucose metabolism. An elevated ratio of certain secondary to primary bile acids can dysregulate both lipid and glucose handling through this receptor.24Frontiers in Microbiology. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease This bile acid-gut microbiome axis is a less obvious but increasingly recognized way that fatty liver disease worsens cholesterol metabolism. It also helps explain why two people with similar diets and similar amounts of liver fat can end up with very different lipid profiles.
The Thyroid Connection
Thyroid hormones are powerful regulators of how the liver handles fat and cholesterol. Even mild underactivity of the thyroid gland has been associated with both higher triglycerides and cholesterol levels and with fatty liver itself.25PubMed Central. Direct effects of thyroid hormones on hepatic lipid metabolism This overlap is more than academic: in practice, an underactive thyroid can worsen fatty liver and its associated lipid problems, while treating the thyroid condition can improve both. The development of resmetirom, which mimics thyroid hormone action specifically in the liver, grew directly out of this biology. If you have fatty liver and abnormal lipids, a thyroid function check is worth discussing with your doctor, especially if the lipid abnormalities seem disproportionate to your weight or diet.
When Familial Hypercholesterolemia Overlaps With Fatty Liver
Some people have genetically very high cholesterol from birth due to familial hypercholesterolemia. When these individuals also develop fatty liver, the combination appears to worsen clinical outcomes. In a national analysis of hospitalizations, patients with familial hypercholesterolemia who also had fatty liver had higher rates of heart failure and pulmonary hypertension, along with more diabetes and anemia, compared to those with familial hypercholesterolemia alone.26ScienceDirect / Journal of Clinical Lipidology. Patients with Familial Hypercholesterolemia with Non-Alcoholic Fatty Liver Disease Have Worse Clinical Outcomes, Nation-Wide Study This overlap matters because clinicians managing genetically elevated cholesterol may not routinely screen for fatty liver, and the added metabolic burden of liver fat can amplify an already serious cardiovascular risk profile.